Z
Ziyu Li
Researcher at Peking University
Publications - 211
Citations - 4022
Ziyu Li is an academic researcher from Peking University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 26, co-authored 172 publications receiving 2519 citations. Previous affiliations of Ziyu Li include Peking Union Medical College.
Papers
More filters
Journal ArticleDOI
Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial
Yanfeng Hu,Chang-Ming Huang,Yihong Sun,Xiangqian Su,Hui Cao,Jiankun Hu,Yingwei Xue,Jian Suo,Kaixiong Tao,Xianli He,Hongbo Wei,Mingang Ying,Weiguo Hu,Xiaohui Du,Pingyan Chen,Hao Liu,Chao-Hui Zheng,Fenglin Liu,Jiang Yu,Ziyu Li,Gang Zhao,Xinzu Chen,Kuan Wang,Ping Li,Jiadi Xing,Guoxin Li +25 more
TL;DR: Experienced surgeons can safely perform LG with D2 lymphadenectomy for AGC, and the morbidity and mortality within 30 days after surgery between the LG and OG groups were compared on the basis of the modified intention-to-treat principle.
Journal ArticleDOI
Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial
Jiang Yu,Chang-Ming Huang,Yihong Sun,Xiangqian Su,Hui Cao,Jiankun Hu,Kuan Wang,Jian Suo,Kaixiong Tao,Xianli He,Hongbo Wei,Mingang Ying,Weiguo Hu,Xiaohui Du,Yanfeng Hu,Hao Liu,Chao-Hui Zheng,Ping Li,Jian-Wei Xie,Fenglin Liu,Ziyu Li,Gang Zhao,Kun Yang,Chunxiao Liu,Hao-jie Li,Pingyan Chen,Jiafu Ji,Guoxin Li +27 more
TL;DR: Among patients with a preoperative clinical stage indicating locally advanced gastric cancer, laparoscopic distal Gastrectomy compared with open distal gastrectomy, did not result in inferior disease-free survival at 3 years.
Journal ArticleDOI
Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications
Zhixue Zheng,Zhaode Bu,Xijuan Liu,Lianhai Zhang,Ziyu Li,Aiwen Wu,Xiaojiang Wu,Xiaojing Cheng,Xiaofang Xing,Hong Du,Xiaohong Wang,Ying Hu,Jiafu Ji +12 more
TL;DR: PD-L1 was elevated in advance gastric cancer patients and may play an important role in tumor immune evasion and patients prognosis and the adenocarcinoma patients with higher up-regulated PD-L 1 expression had much better prognosis than low expression patients.
Journal ArticleDOI
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
Xiaotian Zhang,Han Liang,Ziyu Li,Yingwei Xue,Yanong Wang,Zhiwei Zhou,J Yu,Zhaode Bu,Lin Chen,Yian Du,Xinbao Wang,Aiwen Wu,Guoli Li,Xiangqian Su,Gang Xiao,Ming Cui,Dan Wu,Chen Li,Xiaojiang Wu,Yanbing Zhou,Lianhai Zhang,Chengxue Dang,Yulong He,Zhongtao Zhang,Yihong Sun,Yong Li,Huanqiu Chen,Yuxian Bai,Changsong Qi,Peiwu Yu,Guanbao Zhu,Jian Suo,Baoqing Jia,Leping Li,Chang-Ming Huang,Fei Li,Yingjiang Ye,Huimian Xu,Xin Wang,Yannan Yuan,Jian-Yu E,Xiangji Ying,Chen Yao,Lin Shen,Jiafu Ji +44 more
TL;DR: In this article, the authors evaluated the efficacy and safety of perioperative and postoperative S-1 and oxaliplatin (SOX) compared with postoperative capecitabine (CAPO) in patients with locally advanced gastric cancer undergoing D2 gastrectomy.
Journal ArticleDOI
CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
TL;DR: It is suggested that CCNA2 is a biomarker for the prognosis of ER+ breast cancer and monitoring of tamoxifen efficacy and it's also a promising target for developing new strategies to prevent or even reverse tamoxIFen resistance.